Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Zealand Pharma major shareholder announcement: Polar Capital | ||||
By: GlobeNewswire - 19 Mar 2024 | Back to overview list |
|||
Company announcement – No. 16 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 19 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 18 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 15 March 2024, Polar Capital holds nominally 3,123,349 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 4.98% of the total share capital and total voting rights in Zealand Pharma A/S. Please see further details in the attached notification form. # # # About Zealand Pharma A/S Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a presence in the U.S. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com. Contact:
Attachment |
||||
|
||||
Copyright 2024 GlobeNewswire | Back to overview list |